The USFDA has approved rezafungin, an echinocandin antifungal, for treating candidemia and invasive candidiasis (IC) in adults with no or limited treatment options. The approval of rezafungin is based on safety and efficacy data from two clinical trials. Table 1. Details of clinical trial 1 (NCT03667690) Clinical trial 2 (NCT02734862) 2 Another multicenter, randomized, dose-finding, double-blind study proved safety of rezafungin when used in treatment of candidemia and/or IC.
Adults with with candidemia and/or IC were randomized to receive rezafungin or caspofungin. (Table 2) Table 2 : Intervention arms Primary efficacy endpoint was determined by measuring overall cure rates (resolution of signs of candidemia/IC + mycological eradication) at day 14. The overall cure rates were 60.5% for rezafungin 400 mg, 76.1% for rezafungin 400/200 mg, and 67.2% for caspofungin 70/50 mg.…
